High-Dose Aspirin
Phase 3Small molecule
High-Dose Aspirin is one of 39 small molecule programs targeting Coronary Artery Bypass. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
148 competitors in Coronary Artery Bypass
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaPhase 3
Xe-133
NNobilis Therapeutics Inc.
Phase 3
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Bactroban
PPadagis LLC
Phase 3
Arixtra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Glargine Insulin
AstraZenecaPhase 3
Low-Dose Aspirin
PPharmaEssentia Japan K.K.
Phase 3
Iron Sulphate
PPierre Fabre Pharma GmbH
Phase 3
Pexelizumab
AstraZenecaPhase 3
Acadesine
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Coronary Artery Bypass1 trial
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
Recruiting·DDolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.·Phase 3·NCT07195149·1,703 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for High-Dose Aspirin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details